Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation.

International journal of hematology - 1 Sept 2022

Biavasco Francesca, Zeiser Robert

Abstract excerpt

The curative potential of allogeneic hematopoietic cell transplantation (allo-HCT) for acute myeloid leukemia (AML) relies on the graft-versus-leukemia (GVL)-effect. Relapse after allo-HCT occurs in a considerable proportion of patients, and has a dismal prognosis with very limited curative potential, especially for patients with FLT-ITD-mutated AML. Since the first description of sorafenib for treatment of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to fms-Like Tyrosine Kinase 3
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Recurrence

Share to Transplantation, Homologous

Source

Open in PubMed Open full text

Identifiers

PMID: 35460465
DOI: 10.1007/s12185-022-03352-6
PMCID: PMC9392688

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation.PMID 35460465Read ↗

Post-transplant sorafenib effectively prevents relapse in FLT3-mutated acute myeloid leukemia.Semantic proximity Read ↗

[The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].Semantic proximity Read ↗

Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.Semantic proximity Read ↗

Sorafenib prevents AML relapse after allo-HSCT.Semantic proximity Read ↗

Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation.Semantic proximity Read ↗

TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review.Semantic proximity Read ↗

FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review.Semantic proximity Read ↗

Inhibition of FLT3 in AML: a focus on sorafenib.Semantic proximity Read ↗

Advances in clinical studies of FLT3 inhibitors in acute myeloid leukemia.Semantic proximity Read ↗

Characteristics and Outcome of FLT3-ITD-Positive Acute Myeloid Leukemia.Semantic proximity Read ↗

Strategies targeting FLT3 beyond the kinase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.